Jantibody immunotherapy (Massachusetts General Hospital)

N/A

Report date: 2025/01/26 18:01:45

Base Information

Drug NameJantibody immunotherapy (Massachusetts General Hospital)
Drug Alias Namemesothelin-targeting fusion protein (Massachusetts General Hospital)Jantibody immunotherapy (H-CYTE)mesothelin-targeting fusion protein (H-CYTE)VIC-008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate
Mechanisms of ActionMesothelin modulatorsMesothelin inhibitors
TargetsMesothelin
Therapy Area/IndicationsOvarian NeoplasmsPancreatic NeoplasmsMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe General Hospital Corporation D/B/A Massachusetts General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesInnoveren Scientific Inc
Inactive CompaniesThe General Hospital Corporation D/B/A Massachusetts General Hospital
Active IndicationsOvarian NeoplasmsPancreatic NeoplasmsMesothelioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A